ARTICLE | Product Development
Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei
July 17, 2020 12:55 AM UTC
Two days after FDA granted Fast Track designation to two of BioNTech’s partnered COVID-19 vaccine candidates, one of the products advanced closer to human testing in China.
Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) announced Tuesday that China’s National Medical Products Administration (NMPA) accepted an IND for BNT162b1, one of four COVID-19 vaccine candidates in the BNT162 program...